Our global list of drug combinations
The following is a list of products listed by our company, which is only for medical professionals to refer to.
YISAIPU （Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
|Indication||Manufacturing base||Dosage form & Dosage|
Moderate to severe rheumatoid arthritis;
Moderate to severe plaque psoriasis (PS) in adults aged 18 or above;
Active ankylosing spondylitis.
|Shanghai manufacturing base||12.5 mg/bottle; 25 mg/bottle|